SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is experiencing significant bullish conversation, primarily driven by positive technical indicators like a green Heikin Ashi candle and an upward pivot on the 50 EMA, signaling potential for further upside. The community is actively discussing a price surge, with many expressing confidence in Dogecoin's ability to rally and even outperform broader crypto market trends.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is heavily trending amid an approaching shareholder meeting where a significant increase in authorized shares is up for vote, driving intense debate within the community regarding potential dilution versus long-term growth opportunities. Many investors are frustrated by the stock's current performance, which has lagged Ethereum's recent movements, while supporters eye the broader context of ETH's staking yields and the tokenization movement as catalysts for future appreciation once the uncertainty surrounding the vote is resolved.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is actively trending as its dedicated community relentlessly champions its transformation from a memecoin into a permissionless brand, launching numerous real-world products like KenduSpice and Kendu Energy drinks. The community is fiercely bullish, emphasizing sustained "IRL efforts" and a long-term vision to build a household name within the crypto space.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is highly active after a significant downgrade and "Sell" rating from Goldman Sachs spurred widespread discussion. The community is sharply divided, with many seeing the move as institutional manipulation designed to depress the stock for cheaper accumulation, while others underscore ongoing concerns regarding the company's profit margins and management execution. As a critical infrastructure provider in the booming AI sector, investors are closely watching how the company navigates these challenges.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is actively trending ahead of its CEO's JPM Healthcare Conference presentation, fueled by strong preliminary Q4 results and robust 2026 revenue guidance for its MS drug, Briumvi. The community is debating Briumvi's "best-in-class" profile and its path to blockbuster status, along with the highly anticipated SubQ formulation. Despite operational success, many investors express frustration over the stock's suppressed performance, leading to discussions around market manipulation, potential catalysts, and a long-awaited acquisition.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing significant upward momentum, with community discussions centered on a potential breakout past crucial resistance levels, fueled by reports of increasing international adoption amid currency instability and anticipation of regulatory clarity. This surge is creating notable bullish sentiment and short liquidation events, as traders eye further upside after a period of consolidation.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is actively discussed for its initiatives to address the power consumption of AI data centers, committing to ensure local communities do not bear increased electricity costs. This strategy is fueling debate among investors regarding its long-term financial implications and competitive advantage against rivals in the evolving AI landscape. The community is closely watching if recent price action reflects a buying opportunity or continued softness ahead of the anticipated earnings report.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a focal point due to intense speculation surrounding its reported all-cash revised bid for Warner Bros. Discovery, a move that comes amidst a contentious bidding war and legal challenges from a rival suitor. The community is sharply divided, with bulls anticipating a significant run-up and potential short squeeze ahead of upcoming earnings, while cautious investors highlight potential regulatory hurdles and the stock's recent volatility. This acquisition drama underscores the ongoing strategic battle for content and market share within the streaming industry.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending amidst its escalating hostile takeover attempt for Warner Bros. Discovery, which the WBD board is reportedly poised to reject in favor of Netflix's offer. The community is heavily discussing PSKY's superior all-cash bid and a new Delaware lawsuit challenging WBD's valuation transparency and fiduciary duties, suggesting the board prioritizes personal benefits over shareholder value and raising questions about regulatory hurdles for any Netflix deal.

Ambitions Enterprise Management Co. LLC operates as a travel agency. It provides event planning and management services. The firm also offers transportation, accommodations, meals, and guided tours or activities under convenient packages. The company was founded on October 26, 2023 and is headquartered in Dubai, United Arab Emirates.

Ambitions Enterprise Management Co LLC - Ordinary Shares - Class A

Ambitions Enterprise Management Co LLC

Ambitions Enterprise Management Co. (AHMA) is actively trending due to a significant surge in both price and trading volume. This rapid movement is fueling community discussions about its notably low float, leading to speculation around a potential short squeeze, with many drawing parallels to past parabolic runners despite the absence of clear fundamental news and some concerns about potential share offerings.

statis crypto Watchlist

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$QURE If interested, two coverages on today&#39;s news: https://www.fiercebiotech.com/biotech/uniqure-ballyhooed-gene-therapy-huntingtons-hits-fda-roadblock?utm_medium=email&amp;utm_source= &amp; https://www.biospace.com/drug-development/fda-does-about-face-on-uniqures-huntingtons-gene-therapy?utm_campaign=

Andres

Maria Dan.

DamdD23

The FDA is said to be making a U-turn on uniQure's one-time gene therapy candidate for Huntington's disease despite the treatment being hailed as a game changer. | FDA is said to be making a U-turn on uniQure's one-time gene therapy candidate for Huntington's disease despite the treatment being hailed as a game changer.

Fierce Biotech

uniQure's ballyhooed gene therapy for Huntington's hits FDA roadblock

A month after sparking optimism for patients with Huntington's disease with highly positive data for AMT-130, uniQure revealed Monday that the FDA may be changing its tune on the evidence required for an approval application, a change of direction Stifel called "very challenging" for uniQure.

BioSpace

FDA Does 'About-Face' on UniQure's Huntington's Gene Therapy

StockTwits Web

uniQure NV

 If interested, two coverages on today's news: 

Precigen Inc

Ultragenyx Pharmaceutical Inc

Larimar Therapeutics Inc

Mereo Biopharma

Replimune Group Inc

Sana Biotechnology Inc

aTyr Pharma, Inc

CC Abbott

@CC_Abbott thank you! I was wondering maybe there are some holes in the data that we are not aware of?

StockTwits for iOS

 thank you! I was wondering maybe there are some holes in the data that we are not aware of?

MeiraGTx Holdings plc

@MariaAAAAA small number of patients 12 out of 29 in high dose group have 3 yrs data, use of well-matched external control [from HD natural history study data base] and no need for additional p3 are all known &amp;  AGREED by the FDA previously to support a BLA filing for the accelerated approval. 
 
No, data here is not the issue, imo. The U-turn in the FDA&#39;s views is.

 small number of patients 12 out of 29 in high dose group have 3 yrs data, use of well-matched external control [from HD natural history study data base] and no need for additional p3 are all known &  AGREED by the FDA previously to support a BLA filing for the accelerated approval. 
 
No, data here is not the issue, imo. The U-turn in the FDA's views is.

@MariaAAAAA To be more exact, n=29=17 (high dose group)+12 (low dose group) is the whole group from their p1/2 pivotal trial.  See screen shot below.

 To be more exact, n=29=17 (high dose group)+12 (low dose group) is the whole group from their p1/2 pivotal trial.  See screen shot below.

@CC_Abbott so for you there is enough evidence that it is an unequivocally efficacious drug ? For me the fact that the FDA was previously aligned is not an argument for approval on its own. The validity and strength of the data is what counts.

 so for you there is enough evidence that it is an unequivocally efficacious drug ? For me the fact that the FDA was previously aligned is not an argument for approval on its own. The validity and strength of the data is what counts.

@MariaAAAAA The short answer is Yes.  &quot;unequivocally efficacious&quot; is a very high standard, which probably only exist in a perfect world. 
 
In the current case, 12 symptomatic TREATED HD patients are much BETTER off at yr 3 than hundreds of well-matched, diagnosed, symptomatic Untreated HD patients.   
 
Could it be something other than AMT-130 that accounts for the difference?  Not impossible, but highly unlikely, imo.

 The short answer is Yes.  "unequivocally efficacious" is a very high standard, which probably only exist in a perfect world. 
 
In the current case, 12 symptomatic TREATED HD patients are much BETTER off at yr 3 than hundreds of well-matched, diagnosed, symptomatic Untreated HD patients.   
 
Could it be something other than AMT-130 that accounts for the difference?  Not impossible, but highly unlikely, imo.